BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12857959)

  • 1. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine.
    Luo Y; Zhou H; Mizutani M; Mizutani N; Reisfeld RA; Xiang R
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8850-5. PubMed ID: 12857959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
    Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
    Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis.
    Reisfeld RA; Niethammer AG; Luo Y; Xiang R
    Int Arch Allergy Immunol; 2004 Mar; 133(3):295-304. PubMed ID: 14988601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer.
    Lee SH; Mizutani N; Mizutani M; Luo Y; Zhou H; Kaplan C; Kim SW; Xiang R; Reisfeld RA
    Cancer Immunol Immunother; 2006 Dec; 55(12):1565-74. PubMed ID: 16565828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis.
    Reisfeld RA; Niethammer AG; Luo Y; Xiang R
    Immunol Rev; 2004 Jun; 199():181-90. PubMed ID: 15233734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen.
    Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF
    Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
    U'Ren L; Kedl R; Dow S
    Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction of a DNA vaccine against extracellular domain 1-3 of Flk1 and its inhibitory effect on growth of liver cancer cell line H22].
    Lu F; Qin ZY; Li YM; Qi YX; Liu YF; Yang WB
    Ai Zheng; 2004 Dec; 23(12):1616-21. PubMed ID: 15601548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of GM-CSF immune accessory effects in tumor-bearing mice by direct gene immunization.
    Dou J; Hong X; Zhao F; Wang J; Chen J; Chen G
    Immunol Invest; 2006; 35(2):227-37. PubMed ID: 16698679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth.
    Ruan Z; Yang Z; Wang Y; Wang H; Chen Y; Shang X; Yang C; Guo S; Han J; Liang H; Wu Y
    J Immunother; 2009 Jun; 32(5):486-91. PubMed ID: 19609240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
    Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
    Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.